Reports & eBooks

Drug Pipeline & Clinical Update - June 2024

July 11, 2024

Capital Rx

Highlights

  • Three key new drug approvals, including Iqirvo® for PBC, an autoimmune disease
  • Eight (8) notable expanded indications
  • Four (4) biosimilar approvals (alternatives to Eylea® and Soliris®) and one generic launch
  • Capital Rx's Updated Drug Recall Report: CLICK HERE to review

Capital Rx's Clinical Team closely monitors the drug landscape to provide our clients with timely information on newly FDA-approved medications, as well as products in the pipeline. Read on to review our June 2024 Monthly Drug Update!

Key New Drug Approvals

Onyda™ (clonidine) oral suspension

Approval Date: 05/24/2024 - CLICK HERE for the press release

Indication: Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age or older

Cost*: TBD

Key Considerations:

Iqirvo® (elafibranor) tablet

Approval Date: 06/06/2024 - CLICK HERE for the press release

Indication: Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults

Cost*: $11,500 per month

Key Considerations:

Sofdra™ (sofpironium) topical gel

Approval Date: 06/18/2024 - CLICK HERE for the press release

Indication: Treatment of primary axillary hyperhidrosis in patients 9 year of age and older

Cost*: TBD

Key Considerations:

Notable Expanded Indications

Retevmo® (selpercatinib) – expanded to treat advanced or metastatic medullary thyroid cancer (MTC) with RET mutation in patients 2 year of age and older; expanded to treat advanced or metastatic thyroid cancer with a RET gene fusion in patients 2 years of age and older

Motpoly XR™ (lacosamide) – expanded to treat primary generalized tonic-clonic seizures in patients weighing at least 50 kg as adjunctive therapy

Xigduo® XR (dapagliflozin/metformin) – expanded to improve glycemic control in patients 10 years of age and older with type 2 diabetes

Farxiga® (dapagliflozin) – expanded to improve glycemic control in patients 10 years of age and older with type 2 diabetes

Augtyro™ (repotrectinib) – expanded to treat solid tumors that have a neurotrophic tyrosine receptor kinase (NRTK) gene fusion in patients 12 years and older

Wakix® (pitolisant) – expanded to treat excessive day-time sleepiness in patients 6 years of age and older

Krazati® (adagrasib) – expanded to treat colorectal cancer in combination with cetuximab

Klysri® (tirbanibulin) – expanded to include the treatment of actinic keratosis on areas of the face or scalp up to 100cm2

Biosimilar Approvals

Yesafili™ (aflibercept-jbvf) intravitreal injection

Approval Date: 05/20/2024 - CLICK HERE for the press release

Indication: Treatment of Neovascular (wet) Age-Related Macular Degeneration (AMD), treatment of Macular Edema following Retinal Vein Occlusion (RVO), treatment of Diabetic Macular Edema (DME), treatment of Diabetic Retinopathy (DR)

Additional Information:

Opuviz™ (aflibercept-ysvy) intravitreal injection

Approval Date: 05/20/2024 - CLICK HERE for the press release

Indication: Treatment of Neovascular (wet) Age-Related Macular Degeneration (AMD), treatment of Macular Edema following Retinal Vein Occlusion (RVO), treatment of Diabetic Macular Edema (DME), treatment of Diabetic Retinopathy (DR)

Additional Information:

Bkemv™ (eculizumab-aeeb) IV

Approval Date: 05/28/2024 - CLICK HERE for the press release

Indication: Treatment of paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis; treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy

Additional Information:

Ahzantive® (Aflibercept) intravitreal injection

Approval Date: 06/28/2024 - CLICK HERE for the press release

Indication: Treatment of patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Macular Edema following Retinal Vein Occlusion (RVO)

Additional Information:

Generic Launches

Emflaza® (deflazacort 22.75 mg/mL) oral suspension

Contact Us if you'd like to learn more about Capital Rx's full-service pharmacy benefit management (PBM) solutions and clinical programs.

--------

* Cost: actual patient out-of-pocket costs may be lower, as the list price does not reflect insurance coverage, co-pay support for eligible patients, or financial assistance from patient support

DOWNLOAD NOWBack to Insights

Sign up for our newsletter!

Get the latest information on JUDI news, webinars, and industry insights through our newsletter. Sign up now!